To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Global Cancer Biomarkers Market size was valued at USD 26.61 Billion in 2024 and is poised to grow from USD 29.75 Billion in 2025 to USD 72.61 Billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026–2033).

    Cancer biomarkers providers around the world are estimated to focus on research to maximize their business potential and stay competitive. Developing new therapeutics for specific cancer indications will also be a preferred strategy for new as well as leading cancer biomarkers companies. Market players can also benefit from government support to take their oncology research capabilities to the next level. Use of advanced drug discovery and development techniques will also be popular among cancer biomarker providers in the future. 'F. Hoffmann-La Roche Ltd. (Switzerland)', 'Thermo Fisher Scientific Inc. (US)', 'Qiagen (Netherlands)', 'Bio-Rad Laboratories, Inc. (US)', 'Illumina, Inc. (US)', 'Agilent Technologies, Inc. (US)', 'Abbott Laboratories (US)', 'BioMerieux (France)', 'Merck KGaA (Germany)', 'Becton, Dickinson and Company (US)', 'Myriad Genetics, Inc. (US)', 'Sysmex Corporation (Japan)', 'Hologic, Inc. (US)', 'Quest Diagnostics (US)', 'Centogene N.V. (Germany)', 'BioGenex (US)', 'Siemens Healthineers (Germany)', 'Exact Sciences (US)', 'R&D Systems, Inc. (US, part of Bio-Techne)', 'Biovision Inc. (US)', 'Olink (Sweden)', 'Meso Scale Diagnostics, LLC (US)', 'Invivoscribe, Inc. (US)', 'INOVIQ Ltd. (Australia)'

    Poor lifestyle choices and growing adoption of unhealthy habits have significantly increased the number of people suffering from cancer. This surge in incidence of cancer around the world is a key factor promoting cancer biomarker demand as they play a vital role in cancer diagnostics as well as treatment.

    Multi-Omics Approach to Biomarker Development: Cancer biomarker companies can focus on multi-omics approach to stand out from the competition. This holistic approach integrates genomics, transcriptomics, proteomics, metabolomics, and epigenomics to improve specificity of biomarkers. Multi-omics allows researchers to identify complex biomarker signatures rather than relying on single analytes. By capturing the full molecular landscape of cancer, multi-omics accelerates precision oncology and enhances the clinical utility of biomarkers.

    Why is North America the Top User of Cancer Biomarkers?

    Feedback From Our Clients

    Global Cancer Biomarkers Market

    Report ID: SQMIG35H2355

    $5,300
    BUY NOW